Shares of Venus Remedies were trading 5% higher on 19 June after the Pan American Health Organization (PAHO) issued a sizable oncology tender to Venus Remedies for supplying essential cancer drugs.

In a stock exchange filing, Venus Remedies stated that the partnership will assist the company in providing cancer patients in numerous American countries with access to essential pharmaceuticals.

Many important cancer medications, including methotrexate, bleomycin, cisplatin, carboplatin, cytarabine, doxorubicin, and irinotecan, will be supplied by the company.

The PAHO-backed initiative highlights Venus Remedies’ dedication to providing high-quality pharmaceuticals and improving global health outcomes, according to the company. PAHO, the Pan American Health Organization, is the world’s oldest international public health organization

The agreement demonstrates the company’s capacity to maintain global healthcare standards as well as its expanding market share in the oncology industry.

Earlier in June, UNICEF awarded Venus Remedies a contract to supply beta-lactam antibiotics, specifically Ceftriaxone 1 mg. Ceftriaxone is an antibiotic used to treat bacterial infections. 

This achievement shows the company’s dedication to quality as it maintains UNICEF-accredited good manufacturing practices (GMP).

Venus Remedies announced in January that it has received approval to market two novel drugs in Europe. The approvals include Docetaxel in single vial doses of 160 mg/8 mL, 20 mg/1 mL, and 80 mg/4 mL, as well as a 1g concentration of Gemcitabine from Malta. Both drugs are used in chemotherapy treatments.

At 2:55 pm, the shares of Venus Remedies were trading 0.98% higher at Rs 380 on NSE.